monkey

Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an IgG antibody inhibitor derived from American hamster, targeting ICOS/CD278 in mice, rats, monkeys, and humans.

Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is an IgG2a, κ monoclonal antibody derived from mice, designed to inhibit MDR-1/CD243 proteins in monkeys or humans.

Anti-Monkey/HumanCD28Antibody (CD28.2) is a mouse-derived IgG1, κ antibody inhibitor targeting monkey or human CD28.

Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b, κ antibody inhibitor targeting CD20 in monkeys and humans.

Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is an IgG2a inhibitor derived from mice that targets CD40L/CD154 in monkeys and humans.

Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an IgG antibody inhibitor targeting TGF-β in multiple species including mouse, human, rabbit, monkey, hamster, dog, and cow. For information on the isotype control, refer to Mouse IgG1 kappa, Isotype Control.

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is an IgG2a, κ antibody inhibitor derived from mice that targets monkey or human MHC class II.

Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab can inhibit the production of cytokines downstream of IL-23 signaling pathway, and can be used in the study of psoriatic arthritis.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

Ogalvibart (C-135-LS), a humanized anti-SARS-CoV-2 IgG1 type monoclonal antibody, specifically targets and binds to the spike (S) glycoprotein receptor-binding domain (RBD) of the SARS-CoV-2 virus. When combined with C144LS in a 1:1 ratio, Ogalvibart demonstrates significant preventive activity and effectively prevents the progression of COVID-19 in a rhesus monkey disease model [1].

Lumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody production for the study of allergic diseases.

Alomfilimab (KY-1044) is a humanized monoclonal antibody targeting the inducible co-stimulator receptor (ICOS). As a selective ICOS blockade, it manipulates ICOS expression heterogeneity on T-cell subtypes. It can be used to study tumors.

Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].

Getagozumab is a humanized IgG4-kappa monoclonal antibody that specifically targets endothelin receptor type A (EDNRA) with potent antagonistic activity. Getagozumab significantly lowered pulmonary arterial pressure in both hypoxia-induced and monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) monkey models and further attenuated the associated pulmonary arterial and right ventricular hypertrophy.